THERAPEUTIC TOLEROGENIC ANTIBODIES - Isis Project No 689

Isis Project Numbers 0009 & 0689

THERAPEUTIC AREAS

Treatments using any immuno or peptide based therapeutic agent that has or may have the potential for tolerance problems when administered in humans.

Marketing Opportunity

Therapeutic antibodies were proposed as a promising treatment for a multitude of diseases, including cancer, in the late 70’s and 80’s. However, when protein based biologicals are administered as therapeutic agents patients generally produce an adverse response to the introduction of the foreign biological to their system. This response can become progressively worse to an extent that the therapeutic agents have to be withdrawn. The most well studied therapeutic protein biologicals are antibodies. The incidence of patients receiving antibody therapeutics progressing to "therapy rejection" is increasing with time. This problem of therapeutic rejection is not limited to antibodies and all protein therapeutics may give rise to complications. These complications are typically due to immunological responses against the therapeutic agent itself.

The Oxford Invention

Oxford University has developed a platform technology, from Professor Herman Waldmann's laboratories (the William Dunn School of Pathology), that can be used to alleviate these complications and this can open new therapeutic areas previously abandoned as well as rescue existing failing treatments.

Request Further Information: Project Number 689 Therapeutic Tolerogenic Antibodies